Evidence map›Paper›PMID 30984166›Full record

ArticleFrontiers in immunology2019

Causes and Consequences of miR-150-5p Dysregulation in Myasthenia Gravis.

Mélanie A Cron, Solène Maillard, Frédérique Truffault, Ambra Vittoria Gualeni, Annunziata Gloghini, Elie Fadel, Julien Guihaire, Anthony Behin, Sonia Berrih-Aknin, Rozen Le Panse

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Circulating miRNAs drive personalized medicine based on subgroup classification in myasthenia gravis patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Review
  15. Review
  16. Article
  17. MicroRNA-regulated B cells in obesity.Immunometabolism (Cobham, Surrey) · 2022
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 3 countries.

Mélanie A CronCenter of Research in Myology, Sorbonne University, INSERM, Association Institute of Myology - UMRS 974, Paris, France.
Solène MaillardCenter of Research in Myology, Sorbonne University, INSERM, Association Institute of Myology - UMRS 974, Paris, France.
Frédérique TruffaultCenter of Research in Myology, Sorbonne University, INSERM, Association Institute of Myology - UMRS 974, Paris, France.
Ambra Vittoria GualeniDepartment of Pathology and Laboratory Medicine, Istituto Nazionale dei Tumori, Milan, Italy.
Annunziata GloghiniDepartment of Pathology and Laboratory Medicine, Istituto Nazionale dei Tumori, Milan, Italy.
Elie FadelMarie Lannelongue Hospital, Paris-Sud University, Le Plessis-Robinson, France.
Julien GuihaireMarie Lannelongue Hospital, Paris-Sud University, Le Plessis-Robinson, France.
Anthony BehinNeuromuscular Disease Center, AIM, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
Sonia Berrih-AkninCenter of Research in Myology, Sorbonne University, INSERM, Association Institute of Myology - UMRS 974, Paris, France.
Rozen Le PanseCenter of Research in Myology, Sorbonne University, INSERM, Association Institute of Myology - UMRS 974, Paris, France.
Centre de Recherche en MyologieInstitut de Myologie · FRCentre Chirurgical Marie Lannelongue · FRFondazione IRCCS Istituto Nazionale dei Tumori · ITHôpital Marie Lannelongue · FRInserm · FRSorbonne Université · FRTumori Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune Myasthenia gravis (MG) is a chronic neuromuscular disease mainly due to antibodies against the acetylcholine receptor (AChR) at the neuromuscular junction that induce invalidating muscle weaknesses. In early-onset MG, the thymus is the effector organ and is often characterized by B-cell infiltrations leading to ectopic germinal center (GC) development. The microRNA miR-150-5p has been previously characterized as a biomarker in MG due to its increase in the serum of patients and its decrease after thymectomy, correlated with an improvement of symptoms. Here, we investigated the causes and consequences of the miR-150 increase in the serum of early-onset MG patients. We observed that miR-150 expression was upregulated in MG thymuses in correlation with the presence of thymic B cells and showed by

Indexed as

AdolescentAdultB-LymphocytesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesFemaleGerminal CenterHumansMaleMicroRNAsMyasthenia GravisProto-Oncogene MasProto-Oncogene Proteins c-mybReceptors, NicotinicThymus GlandMAS1 protein, humanMicroRNAsMIR150, humanMYB protein, humanProto-Oncogene MasProto-Oncogene Proteins c-mybReceptors, Nicotinicantimir-150autoimmunitygerminal centermicroRNAMYB

Identifiers

PMID30984166
PMCPMC6450174
OpenAlexW2929475874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.